Table 2 Open in new tab Hazard ratios...

Endpoint	n−3 FAs (N = 12 933)	Placebo (N = 12 938)	HR	95% CI
Cardiovascular disease (CVD), primary and secondary outcomes
Major CVD event^b,c	386	419	0.92	0.80–1.06
Expanded CVD event^d	527	567	0.93	0.82–1.04
Total myocardial infarction (MI)	145	200	0.72	0.59–0.90
Total stroke	148	142	1.04	0.83–1.31
Cardiovascular mortality	142	148	0.96	0.76–1.21
Other vascular outcomes^e
Percutaneous coronary intervention (PCI)	162	208	0.78	0.63–0.95
Coronary artery bypass graft (CABG)	85	86	0.99	0.73–1.33
Fatal MI	13	26	0.50	0.26–0.97
Coronary heart disease (CHD) mortality	37	49	0.76	0.49–1.16
Total CHD^f	308	370	0.83	0.71–0.97
Ischaemic stroke	111	116	0.96	0.74–1.24
Hemorrhagic stroke	25	19	1.32	0.72–2.39
Fatal stroke	22	20	1.10	0.60–2.01
Ancillary outcomes
First hospitalization for heart failure	244	255	0.96	0.80–1.14
Recurrent hospitalization for heart failure	326	379	0.86	0.74–0.998
Atrial fibrillation	469	431	1.09	0.96–1.24
Excluding the first two years of follow-up:
Major CVD event	269	301	0.89	0.76–1.05
Total MI	94	131	0.72	0.55–0.93
Total stroke	103	112	0.92	0.70–1.20

Endpoint

n−3 FAs (N = 12 933)

Placebo (N = 12 938)

95% CI

No. of participants w/event

Cardiovascular disease (CVD), primary and secondary outcomes

Major CVD event^b,c

386

419

0.92

0.80–1.06

Expanded CVD event^d

527

567

0.93

0.82–1.04

Total myocardial infarction (MI)

145

200

0.72

0.59–0.90

Total stroke

148

142

1.04

0.83–1.31

Cardiovascular mortality

142

148

0.96

0.76–1.21

Other vascular outcomes^e

Percutaneous coronary intervention (PCI)

162

208

0.78

0.63–0.95

Coronary artery bypass graft (CABG)

0.99

0.73–1.33

Fatal MI

0.50

0.26–0.97

Coronary heart disease (CHD) mortality

0.76

0.49–1.16

Total CHD^f

308

370

0.83

0.71–0.97

Ischaemic stroke

111

116

0.96

0.74–1.24

Hemorrhagic stroke

1.32

0.72–2.39

Fatal stroke

1.10

0.60–2.01

Ancillary outcomes

First hospitalization for heart failure

244

255

0.96

0.80–1.14

Recurrent hospitalization for heart failure

326

379

0.86

0.74–0.998

Atrial fibrillation

469

431

1.09

0.96–1.24

Excluding the first two years of follow-up:

Major CVD event

269

301

0.89

0.76–1.05

Total MI

131

0.72

0.55–0.93

Total stroke

103

112

0.92

0.70–1.20

Endpoint	n−3 FAs (N = 12 933)	Placebo (N = 12 938)	HR	95% CI
Cardiovascular disease (CVD), primary and secondary outcomes
Major CVD event^b,c	386	419	0.92	0.80–1.06
Expanded CVD event^d	527	567	0.93	0.82–1.04
Total myocardial infarction (MI)	145	200	0.72	0.59–0.90
Total stroke	148	142	1.04	0.83–1.31
Cardiovascular mortality	142	148	0.96	0.76–1.21
Other vascular outcomes^e
Percutaneous coronary intervention (PCI)	162	208	0.78	0.63–0.95
Coronary artery bypass graft (CABG)	85	86	0.99	0.73–1.33
Fatal MI	13	26	0.50	0.26–0.97
Coronary heart disease (CHD) mortality	37	49	0.76	0.49–1.16
Total CHD^f	308	370	0.83	0.71–0.97
Ischaemic stroke	111	116	0.96	0.74–1.24
Hemorrhagic stroke	25	19	1.32	0.72–2.39
Fatal stroke	22	20	1.10	0.60–2.01
Ancillary outcomes
First hospitalization for heart failure	244	255	0.96	0.80–1.14
Recurrent hospitalization for heart failure	326	379	0.86	0.74–0.998
Atrial fibrillation	469	431	1.09	0.96–1.24
Excluding the first two years of follow-up:
Major CVD event	269	301	0.89	0.76–1.05
Total MI	94	131	0.72	0.55–0.93
Total stroke	103	112	0.92	0.70–1.20

Table 2

Open in new tab

Hazard ratios (HR) and 95% confidence intervals (CI) of cardiovascular outcomes by randomized assignment to n−3 fatty acids (n−3 FAs)^a

Endpoint	n−3 FAs (N = 12 933)	Placebo (N = 12 938)	HR	95% CI
Endpoint	No. of participants w/event		HR	95% CI
Cardiovascular disease (CVD), primary and secondary outcomes
Major CVD event^b,c	386	419	0.92	0.80–1.06
Expanded CVD event^d	527	567	0.93	0.82–1.04
Total myocardial infarction (MI)	145	200	0.72	0.59–0.90
Total stroke	148	142	1.04	0.83–1.31
Cardiovascular mortality	142	148	0.96	0.76–1.21
Other vascular outcomes^e
Percutaneous coronary intervention (PCI)	162	208	0.78	0.63–0.95
Coronary artery bypass graft (CABG)	85	86	0.99	0.73–1.33
Fatal MI	13	26	0.50	0.26–0.97
Coronary heart disease (CHD) mortality	37	49	0.76	0.49–1.16
Total CHD^f	308	370	0.83	0.71–0.97
Ischaemic stroke	111	116	0.96	0.74–1.24
Hemorrhagic stroke	25	19	1.32	0.72–2.39
Fatal stroke	22	20	1.10	0.60–2.01
Ancillary outcomes
First hospitalization for heart failure	244	255	0.96	0.80–1.14
Recurrent hospitalization for heart failure	326	379	0.86	0.74–0.998
Atrial fibrillation	469	431	1.09	0.96–1.24
Excluding the first two years of follow-up:
Major CVD event	269	301	0.89	0.76–1.05
Total MI	94	131	0.72	0.55–0.93
Total stroke	103	112	0.92	0.70–1.20

Endpoint	n−3 FAs (N = 12 933)	Placebo (N = 12 938)	HR	95% CI
Endpoint	No. of participants w/event		HR	95% CI
Cardiovascular disease (CVD), primary and secondary outcomes
Major CVD event^b,c	386	419	0.92	0.80–1.06
Expanded CVD event^d	527	567	0.93	0.82–1.04
Total myocardial infarction (MI)	145	200	0.72	0.59–0.90
Total stroke	148	142	1.04	0.83–1.31
Cardiovascular mortality	142	148	0.96	0.76–1.21
Other vascular outcomes^e
Percutaneous coronary intervention (PCI)	162	208	0.78	0.63–0.95
Coronary artery bypass graft (CABG)	85	86	0.99	0.73–1.33
Fatal MI	13	26	0.50	0.26–0.97
Coronary heart disease (CHD) mortality	37	49	0.76	0.49–1.16
Total CHD^f	308	370	0.83	0.71–0.97
Ischaemic stroke	111	116	0.96	0.74–1.24
Hemorrhagic stroke	25	19	1.32	0.72–2.39
Fatal stroke	22	20	1.10	0.60–2.01
Ancillary outcomes
First hospitalization for heart failure	244	255	0.96	0.80–1.14
Recurrent hospitalization for heart failure	326	379	0.86	0.74–0.998
Atrial fibrillation	469	431	1.09	0.96–1.24
Excluding the first two years of follow-up:
Major CVD event	269	301	0.89	0.76–1.05
Total MI	94	131	0.72	0.55–0.93
Total stroke	103	112	0.92	0.70–1.20

Analyses were from Cox regression models that were controlled for age, sex, and randomization group in the vitamin D portion of the trial. Analyses were not adjusted for multiple comparisons.

Primary outcomes.

A composite of MI, stroke, and cardiovascular mortality.

A composite of MI, stroke, cardiovascular mortality, and coronary revascularization (CABG, PCI).

Not prespecified as primary or secondary outcomes.

A composite of MI, coronary revascularization (CABG, PCI), and CHD death.

Adapted from Manson et al.¹⁶

This Feature Is Available To Subscribers Only